{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:00:49Z","timestamp":1790974849873,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN261200800001E"],"award-info":[{"award-number":["HHSN261200800001E"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.tips.2009.09.006","type":"journal-article","created":{"date-parts":[[2009,10,17]],"date-time":"2009-10-17T04:21:08Z","timestamp":1255753268000},"page":"638-646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Multiple ways of targeting APOBEC3\u2013virion infectivity factor interactions for anti-HIV-1 drug development"],"prefix":"10.1016","volume":"30","author":[{"given":"Jessica L.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Burdick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay K.","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2009.09.006_bib1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nature07352","article-title":"Challenges in the development of an HIV-1 vaccine","volume":"455","author":"Barouch","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.tips.2009.09.006_bib2","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(08)61593-7","article-title":"Failure of the Merck HIV vaccine: an uncertain step forward","volume":"372","author":"Robb","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2009.09.006_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJM198707233170401","article-title":"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial","volume":"317","author":"Fischl","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2009.09.006_bib4","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/ije\/dym104","article-title":"Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis","volume":"36","author":"Arrive","year":"2007","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.tips.2009.09.006_bib5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/apc.2005.19.563","article-title":"Beyond efficacy: the impact of combination antiretroviral therapy on quality of life","volume":"19","author":"Sax","year":"2005","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.tips.2009.09.006_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0166-3542(95)00926-4","article-title":"Saquinavir\/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte\/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity","volume":"29","author":"Vella","year":"1996","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tips.2009.09.006_bib7","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1086\/315002","article-title":"Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial","volume":"180","author":"Hoen","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tips.2009.09.006_bib8","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.bmcl.2006.11.080","article-title":"A potent and orally active HIV-1 integrase inhibitor","volume":"17","author":"Egbertson","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2009.09.006_bib9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/589289","article-title":"Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents","volume":"47","author":"MacArthur","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tips.2009.09.006_bib10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/COH.0b013e3283223d46","article-title":"A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors","volume":"4","author":"Moore","year":"2009","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.tips.2009.09.006_bib11","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1086\/597290","article-title":"Raltegravir: the first HIV type 1 integrase inhibitor","volume":"48","author":"Hicks","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tips.2009.09.006_bib12","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cub.2004.06.050","article-title":"APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo","volume":"14","author":"Liddament","year":"2004","journal-title":"Curr. Biol."},{"key":"10.1016\/j.tips.2009.09.006_bib13","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1038\/sj.emboj.7600246","article-title":"A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins","volume":"23","author":"Wiegand","year":"2004","journal-title":"EMBO J."},{"key":"10.1016\/j.tips.2009.09.006_bib14","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nature00939","article-title":"Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein","volume":"418","author":"Sheehy","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.tips.2009.09.006_bib15","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1128\/JVI.78.11.6073-6076.2004","article-title":"Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication","volume":"78","author":"Zheng","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib16","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nature02343","article-title":"The cytoplasmic body component TRIM5\u03b1 restricts HIV-1 infection in Old World monkeys","volume":"427","author":"Stremlau","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.tips.2009.09.006_bib17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nature02777","article-title":"Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1","volume":"430","author":"Sayah","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.tips.2009.09.006_bib18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nature06553","article-title":"Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu","volume":"451","author":"Neil","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.tips.2009.09.006_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.chom.2008.03.001","article-title":"The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein","volume":"3","author":"Van Damme","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.tips.2009.09.006_bib20","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/328728a0","article-title":"The HIV \u2018A\u2019 (sor) gene product is essential for virus infectivity","volume":"328","author":"Strebel","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.tips.2009.09.006_bib21","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1126\/science.3497453","article-title":"The sor gene of HIV-1 is required for efficient virus transmission in vitro","volume":"237","author":"Fisher","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.tips.2009.09.006_bib22","doi-asserted-by":"crossref","first-page":"6489","DOI":"10.1128\/jvi.66.11.6489-6495.1992","article-title":"Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes","volume":"66","author":"Gabuzda","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib23","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1128\/jvi.67.8.4945-4955.1993","article-title":"Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells","volume":"67","author":"von Schwedler","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/molbev\/msi026","article-title":"Evolution of the AID\/APOBEC family of polynucleotide (deoxy)cytidine deaminases","volume":"22","author":"Conticello","year":"2005","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.tips.2009.09.006_bib25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1006\/geno.2002.6718","article-title":"An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22","volume":"79","author":"Jarmuz","year":"2002","journal-title":"Genomics"},{"key":"10.1016\/j.tips.2009.09.006_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virol.2005.01.038","article-title":"Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins","volume":"334","author":"Huthoff","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.tips.2009.09.006_bib27","doi-asserted-by":"crossref","first-page":"10522","DOI":"10.1128\/JVI.01123-06","article-title":"Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family","volume":"80","author":"Dang","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib28","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.virol.2008.06.013","article-title":"Functional domain organization of human APOBEC3G","volume":"379","author":"Gooch","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.tips.2009.09.006_bib29","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.virol.2005.01.011","article-title":"Complementary function of the two catalytic domains of APOBEC3G","volume":"333","author":"Navarro","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.tips.2009.09.006_bib30","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1128\/JVI.02680-05","article-title":"Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect","volume":"80","author":"Iwatani","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1742-4690-6-56","article-title":"Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA","volume":"6","author":"Friew","year":"2009","journal-title":"Retrovirology"},{"key":"10.1016\/j.tips.2009.09.006_bib32","doi-asserted-by":"crossref","first-page":"10920","DOI":"10.1074\/jbc.M500382200","article-title":"The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain","volume":"280","author":"Hache","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2009.09.006_bib33","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/jcb.20082","article-title":"Functional domains of APOBEC3G required for antiviral activity","volume":"92","author":"Li","year":"2004","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.tips.2009.09.006_bib34","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/nar\/gki343","article-title":"Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F\/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities","volume":"33","author":"Langlois","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2009.09.006_bib35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2006-10-051763","article-title":"Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression","volume":"110","author":"Peng","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.tips.2009.09.006_bib36","doi-asserted-by":"crossref","first-page":"7645","DOI":"10.1128\/JVI.00206-06","article-title":"Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells","volume":"80","author":"Chen","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib37","doi-asserted-by":"crossref","first-page":"9474","DOI":"10.1128\/JVI.01089-09","article-title":"Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets","volume":"83","author":"Koning","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib38","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1074\/jbc.M610138200","article-title":"Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells","volume":"282","author":"Stopak","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2009.09.006_bib39","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1099\/vir.0.83530-0","article-title":"APOBEC3G upregulation by \u03b1 interferon restricts human immunodeficiency virus type 1 infection in human peripheral plasmacytoid dendritic cells","volume":"89","author":"Wang","year":"2008","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature03493","article-title":"Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells","volume":"435","author":"Chiu","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.tips.2009.09.006_bib41","doi-asserted-by":"crossref","first-page":"15588","DOI":"10.1073\/pnas.0604524103","article-title":"High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition","volume":"103","author":"Chiu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2009.09.006_bib42","doi-asserted-by":"crossref","first-page":"7270","DOI":"10.1128\/MCB.25.16.7270-7277.2005","article-title":"Mice deficient in APOBEC2 and APOBEC3","volume":"25","author":"Mikl","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.tips.2009.09.006_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0092-8674(03)00515-4","article-title":"Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif","volume":"114","author":"Mariani","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.tips.2009.09.006_bib44","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/nm946","article-title":"HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation","volume":"9","author":"Marin","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2009.09.006_bib45","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/nm945","article-title":"The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif","volume":"9","author":"Sheehy","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2009.09.006_bib46","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1097-2765(03)00353-8","article-title":"HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability","volume":"12","author":"Stopak","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tips.2009.09.006_bib47","doi-asserted-by":"crossref","first-page":"35822","DOI":"10.1074\/jbc.M405761200","article-title":"Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs","volume":"279","author":"Svarovskaia","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2009.09.006_bib48","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nature01707","article-title":"The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA","volume":"424","author":"Zhang","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.tips.2009.09.006_bib49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature01709","article-title":"Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts","volume":"424","author":"Mangeat","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.tips.2009.09.006_bib50","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0092-8674(03)00423-9","article-title":"DNA deamination mediates innate immunity to retroviral infection","volume":"113","author":"Harris","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.tips.2009.09.006_bib51","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1126\/science.1083338","article-title":"Hypermutation of HIV-1 DNA in the absence of the Vif protein","volume":"300","author":"Lecossier","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.tips.2009.09.006_bib52","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1093\/nar\/gkh554","article-title":"APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase","volume":"32","author":"Suspene","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2009.09.006_bib53","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nsmb758","article-title":"Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome","volume":"11","author":"Yu","year":"2004","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.tips.2009.09.006_bib54","doi-asserted-by":"crossref","first-page":"44412","DOI":"10.1074\/jbc.C300376200","article-title":"The enzymatic activity of CEM15\/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity","volume":"278","author":"Shindo","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2009.09.006_bib55","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.virol.2007.03.022","article-title":"Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F","volume":"365","author":"Yang","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.tips.2009.09.006_bib56","doi-asserted-by":"crossref","first-page":"11710","DOI":"10.1128\/JVI.01038-06","article-title":"Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication","volume":"80","author":"Guo","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib57","doi-asserted-by":"crossref","first-page":"11322","DOI":"10.1128\/JVI.00162-07","article-title":"The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA","volume":"81","author":"Guo","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib58","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1093\/nar\/gkm750","article-title":"Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G","volume":"35","author":"Iwatani","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2009.09.006_bib59","doi-asserted-by":"crossref","first-page":"e1000231","DOI":"10.1371\/journal.ppat.1000231","article-title":"APOBEC3G inhibits elongation of HIV-1 reverse transcripts","volume":"4","author":"Bishop","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tips.2009.09.006_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2008.01.042","article-title":"APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells","volume":"375","author":"Anderson","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.tips.2009.09.006_bib61","doi-asserted-by":"crossref","first-page":"32065","DOI":"10.1074\/jbc.M703423200","article-title":"APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription","volume":"282","author":"Li","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2009.09.006_bib62","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1074\/jbc.M607298200","article-title":"APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G","volume":"282","author":"Holmes","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2009.09.006_bib63","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cub.2004.12.068","article-title":"Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity","volume":"15","author":"Newman","year":"2005","journal-title":"Curr. Biol."},{"key":"10.1016\/j.tips.2009.09.006_bib64","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1128\/JVI.00272-07","article-title":"Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration","volume":"81","author":"Mbisa","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib65","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1128\/JVI.02584-06","article-title":"Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation","volume":"81","author":"Luo","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib66","doi-asserted-by":"crossref","first-page":"13346","DOI":"10.1128\/JVI.01361-07","article-title":"Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1","volume":"81","author":"Miyagi","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib67","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1128\/JVI.02391-07","article-title":"The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction","volume":"82","author":"Schumacher","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib68","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.virol.2006.10.036","article-title":"Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions","volume":"360","author":"Xu","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.tips.2009.09.006_bib69","doi-asserted-by":"crossref","first-page":"11667","DOI":"10.1074\/jbc.M606864200","article-title":"Virion-associated uracil DNA glycosylase-2 and apurinic\/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA","volume":"282","author":"Yang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2009.09.006_bib70","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1128\/JVI.80.2.875-882.2006","article-title":"Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G","volume":"80","author":"Kaiser","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib71","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1128\/JVI.02469-07","article-title":"Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1","volume":"82","author":"Langlois","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib72","doi-asserted-by":"crossref","first-page":"e1000342","DOI":"10.1371\/journal.ppat.1000342","article-title":"Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells","volume":"5","author":"Kamata","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tips.2009.09.006_bib73","doi-asserted-by":"crossref","first-page":"e6571","DOI":"10.1371\/journal.pone.0006571","article-title":"APOBEC3G-depleted resting CD4+ T cells remain refractory to HIV1 infection","volume":"4","author":"Santoni de Sio","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tips.2009.09.006_bib74","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.1128\/JVI.00020-09","article-title":"Cytoplasmic APOBEC3G restricts incoming Vif-positive HIV-1 and increases 2-LTR circle formation in activated T helper subtype cells","volume":"83","author":"Vetter","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib75","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/j.cub.2003.10.034","article-title":"The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G","volume":"13","author":"Conticello","year":"2003","journal-title":"Curr. Biol."},{"key":"10.1016\/j.tips.2009.09.006_bib76","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1074\/jbc.M313093200","article-title":"Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin\u2013proteasome pathway","volume":"279","author":"Mehle","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2009.09.006_bib77","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1126\/science.1089591","article-title":"Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex","volume":"302","author":"Yu","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.tips.2009.09.006_bib78","doi-asserted-by":"crossref","first-page":"9579","DOI":"10.1128\/JVI.79.15.9579-9587.2005","article-title":"Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB\/C E3 ubiquitin ligase","volume":"79","author":"Liu","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib79","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1101\/gad.1249904","article-title":"Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif\u2013Cul5 complex that promotes APOBEC3G degradation","volume":"18","author":"Mehle","year":"2004","journal-title":"Genes Dev."},{"key":"10.1016\/j.tips.2009.09.006_bib80","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1101\/gad.1250204","article-title":"Selective assembly of HIV-1 Vif\u2013Cul5\u2013ElonginB\u2013ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines","volume":"18","author":"Yu","year":"2004","journal-title":"Genes Dev."},{"key":"10.1016\/j.tips.2009.09.006_bib81","doi-asserted-by":"crossref","first-page":"11444","DOI":"10.1073\/pnas.0502440102","article-title":"Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G","volume":"102","author":"Luo","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2009.09.006_bib82","doi-asserted-by":"crossref","first-page":"17259","DOI":"10.1074\/jbc.M602413200","article-title":"A zinc-binding region in Vif binds Cul5 and determines cullin selection","volume":"281","author":"Mehle","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2009.09.006_bib83","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature06638","article-title":"Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G","volume":"452","author":"Chen","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.tips.2009.09.006_bib84","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature07357","article-title":"Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications","volume":"456","author":"Holden","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.tips.2009.09.006_bib85","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/emboj.2008.290","article-title":"Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G","volume":"28","author":"Furukawa","year":"2009","journal-title":"EMBO J."},{"key":"10.1016\/j.tips.2009.09.006_bib86","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jmb.2009.04.031","article-title":"An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model","volume":"389","author":"Harjes","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.tips.2009.09.006_bib87","doi-asserted-by":"crossref","first-page":"8656","DOI":"10.1128\/JVI.00767-08","article-title":"Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly","volume":"82","author":"Stanley","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib88","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/prot.21471","article-title":"Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity","volume":"69","author":"Auclair","year":"2007","journal-title":"Proteins"},{"key":"10.1016\/j.tips.2009.09.006_bib89","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/protein\/gzp004","article-title":"The C-terminal domain of the HIV-1 Vif protein is natively unfolded in its unbound state","volume":"22","author":"Reingewertz","year":"2009","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.tips.2009.09.006_bib90","doi-asserted-by":"crossref","first-page":"11398","DOI":"10.1128\/JVI.77.21.11398-11407.2003","article-title":"The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity","volume":"77","author":"Kao","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib91","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1371\/journal.ppat.0010006","article-title":"Natural variation in Vif: differential impact on APOBEC3G\/3F and a potential role in HIV-1 diversification","volume":"1","author":"Simon","year":"2005","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tips.2009.09.006_bib92","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1128\/JVI.80.6.3112-3115.2006","article-title":"Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F","volume":"80","author":"Tian","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib93","doi-asserted-by":"crossref","first-page":"8201","DOI":"10.1128\/JVI.00395-07","article-title":"Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F","volume":"81","author":"Russell","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib94","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1128\/JVI.00388-06","article-title":"Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G","volume":"80","author":"Schrofelbauer","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib95","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1073\/pnas.0400830101","article-title":"A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion","volume":"101","author":"Xu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2009.09.006_bib96","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1073\/pnas.0307713101","article-title":"A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor","volume":"101","author":"Bogerd","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2009.09.006_bib97","doi-asserted-by":"crossref","first-page":"14481","DOI":"10.1074\/jbc.C400060200","article-title":"A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action","volume":"279","author":"Mangeat","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2009.09.006_bib98","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1073\/pnas.0307132101","article-title":"A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif)","volume":"101","author":"Schrofelbauer","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2009.09.006_bib99","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jmb.2008.06.061","article-title":"Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction","volume":"381","author":"He","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.tips.2009.09.006_bib100","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.micinf.2008.06.003","article-title":"Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G\/F","volume":"10","author":"Yamashita","year":"2008","journal-title":"Microbes Infect."},{"key":"10.1016\/j.tips.2009.09.006_bib101","doi-asserted-by":"crossref","unstructured":"Chen, G. et al. (2009) A patch of positively charged amino acids surrounding the HIV-1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J. Virol. (in press) DOI:10.1128\/JVI.00653-09","DOI":"10.1128\/JVI.00653-09"},{"key":"10.1016\/j.tips.2009.09.006_bib102","doi-asserted-by":"crossref","unstructured":"Dang, Y. et al. (2009) Identification of a novel WxSLVK motif in the N-terminus of HIV and SIV Vif that is critical for APOBEC3G and APOBEC3F neutralization. J. Virol. (in press) DOI:10.1128\/JVI.00651-09","DOI":"10.1128\/JVI.00651-09"},{"key":"10.1016\/j.tips.2009.09.006_bib103","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1128\/JVI.01898-08","article-title":"Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif","volume":"83","author":"Pery","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib104","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1074\/jbc.M210164200","article-title":"Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins","volume":"278","author":"Yang","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2009.09.006_bib105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.virol.2008.04.017","article-title":"The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation","volume":"377","author":"Donahue","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.tips.2009.09.006_bib106","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.virol.2007.08.027","article-title":"Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation","volume":"370","author":"Zhang","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.tips.2009.09.006_bib107","doi-asserted-by":"crossref","first-page":"e3963","DOI":"10.1371\/journal.pone.0003963","article-title":"Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins","volume":"3","author":"Zhang","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tips.2009.09.006_bib108","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1128\/JVI.02795-06","article-title":"Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and virion encapsidation","volume":"81","author":"Huthoff","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib109","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1128\/JVI.01621-08","article-title":"Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif","volume":"83","author":"Russell","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib110","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cub.2008.04.073","article-title":"Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G","volume":"18","author":"Hache","year":"2008","journal-title":"Curr. Biol."},{"key":"10.1016\/j.tips.2009.09.006_bib111","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1128\/JVI.01533-07","article-title":"Role of APOBEC3G\/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors","volume":"82","author":"Gandhi","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib112","doi-asserted-by":"crossref","first-page":"8172","DOI":"10.1128\/JVI.01115-08","article-title":"Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya","volume":"82","author":"Land","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib113","doi-asserted-by":"crossref","first-page":"7805","DOI":"10.1128\/JVI.00280-09","article-title":"Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif","volume":"83","author":"Piantadosi","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib114","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1128\/JVI.79.3.1975-1980.2005","article-title":"G\u2192A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo","volume":"79","author":"Kieffer","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib115","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1073\/pnas.0710190105","article-title":"Cytidine deamination induced HIV-1 drug resistance","volume":"105","author":"Mulder","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2009.09.006_bib116","doi-asserted-by":"crossref","first-page":"e1000367","DOI":"10.1371\/journal.ppat.1000367","article-title":"Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance","volume":"5","author":"Jern","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tips.2009.09.006_bib117","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1742-4690-6-16","article-title":"APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA","volume":"6","author":"Russell","year":"2009","journal-title":"Retrovirology"},{"key":"10.1016\/j.tips.2009.09.006_bib118","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1742-4690-4-81","article-title":"The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G","volume":"4","author":"Miller","year":"2007","journal-title":"Retrovirology"},{"key":"10.1016\/j.tips.2009.09.006_bib119","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1096\/fj.06-6773com","article-title":"Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G","volume":"21","author":"Xiao","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.tips.2009.09.006_bib120","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2174\/0929867024606731","article-title":"Converting a peptide into a drug: strategies to improve stability and bioavailability","volume":"9","author":"Adessi","year":"2002","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.tips.2009.09.006_bib121","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2249.1991.tb05639.x","article-title":"Programmed cell death (apoptosis) in lymphoid and myeloid cell lines during zinc deficiency","volume":"83","author":"Martin","year":"1991","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.tips.2009.09.006_bib122","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1006\/excr.1994.1096","article-title":"Apoptosis is dependent on intracellular zinc and independent of intracellular calcium in lymphocytes","volume":"211","author":"Treves","year":"1994","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.tips.2009.09.006_bib123","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1128\/AAC.49.9.3833-3841.2005","article-title":"High-throughput human immunodeficiency virus type 1 (HIV-1) full replication assay that includes HIV-1 Vif as an antiviral target","volume":"49","author":"Cao","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2009.09.006_bib124","doi-asserted-by":"crossref","first-page":"13235","DOI":"10.1128\/JVI.00204-07","article-title":"Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding","volume":"81","author":"Mehle","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.tips.2009.09.006_bib125","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/nbt.1496","article-title":"Small-molecule inhibition of HIV-1 Vif","volume":"26","author":"Nathans","year":"2008","journal-title":"Nat. Biotechnol."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016561470900162X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016561470900162X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T09:04:39Z","timestamp":1759050279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016561470900162X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":125,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S016561470900162X"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2009.09.006","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple ways of targeting APOBEC3\u2013virion infectivity factor interactions for anti-HIV-1 drug development","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2009.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}